Breast Cancer
Conference Coverage
Ribociclib plus endocrine therapy boosts survival of HR+/HER2- breast cancer
CHICAGO – The overall survival rate at 42 months was 70% in the combined therapy group, vs. 46% for patients treated...
News
FDA approves PI3K inhibitor alpelisib for breast cancer
The PI3K inhibitor is approved for use with fulvestrant for HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer in...
News
Use of Oncotype DX to tailor breast cancer treatment likely to reduce costs
In the wake of the TAILORx trial, routine use of Oncotype DX in women with early breast cancer is expected to increase testing costs but decrease...
Conference Coverage
Diet linked to lower risk of death from breast cancer
A balanced, low-fat diet was associated with a 21% lower risk of death from breast cancer in a randomized study.
News
ICYMI: Alpelisib/fulvestrant combo boosts PFS in advanced breast cancer
Progression-free survival time was almost doubled with alpelisib and fulvestrant, compared with fulvestrant alone.
Conference Coverage
TVEC may improve response rates in nonmetastatic TNBC
ATLANTA – Adding TVEC to neoadjuvant chemotherapy improved pCR rates in patients with nonmetastatic TNBC in a phase...
Opinion
PROs in lung cancer and how to administer trastuzumab
Dr. Alan P. Lyss explains what the PACIFIC and HannaH trials mean for your day-to-day practice.
Conference Coverage
Neoadjuvant removal of DCIS helps identify HER2+ nonsurgical trial candidates
In evaluating the safety of eliminating surgery for patients who are exceptional responders to neoadjuvant systemic therapy, eradication of both...
Conference Coverage
Bioimpedance spectroscopy may better identify lymphedema progression
In an interim analysis from the PREVENT trial, there was a 10% absolute reduction and 67% relative reduction in lymphedema progression in the...
News
Interplay of TP53, ESR2 may expand treatment options for some TNBCs
Study finds interaction of TP53 mutational status and ESR2 expression influences survival in triple-negative breast cancer and suggests tamoxifen...